Zenas BioPharma Touts Phase 3 Win, But Stock Crashes

Zenas BioPharma Inc. (NASDAQ:ZBIO) stock is trading lower on Monday after the company released results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD). IgG4-RD is an immune system disorder where the body creates excess IgG4...